Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TOMOX · 1 trial · 1 indication
pharmacokinetic study
| Arm | Type | Description |
|---|---|---|
| triweekly then biweekly | EXPERIMENTAL | The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks). |
| biweekly then triweekly | EXPERIMENTAL | The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen. |
| Name | Type | Description |
|---|---|---|
| TOMOX | DRUG | - |
| Bevacizumab | DRUG | Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks. |
Inclusion Criteria: * performance status (ECOG-PS) of 0 or 1 * patient with histologically proven colorectal cancer with distant metastases * measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * life expectancy \> 12 months * signed written informed consent Exc...
Top 20 of 77 competitors
TOMOX is an investigational small molecule being studied for the treatment of metastatic colorectal cancer. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
TOMOX is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
TOMOX is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. One Phase 2 clinical trial has been completed.
TOMOX has been studied in one completed Phase 2 clinical trial, identified as NCT02821559. This trial evaluated biweekly versus triweekly raltitrexed with oxaliplatin, with or without bevacizumab, in first-line metastatic colorectal cancer.
TOMOX is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for metastatic colorectal cancer, and its safety and efficacy have not been established.